SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by escalating Middle East tensions, fueling community debate between expectations of deeper market declines amid concerns over oil prices and inflation, and those anticipating a swift recovery from dip-buyers and perceived market intervention.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp (BATL) is soaring on heightened geopolitical tensions surrounding oil supply routes and rising crude prices, igniting a powerful short squeeze as its low float attracts massive retail attention and bullish price targets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Escalating geopolitical tensions in the Middle East, especially around the Strait of Hormuz and its potential impact on oil prices, are driving significant volatility for QQQ. The community is sharply divided, with some anticipating a deeper market correction while others point to resilient 'buy the dip' behavior and perceived market manipulation.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating geopolitical tensions surrounding the Iran conflict and rising crude oil prices, exacerbated by reports of the Strait of Hormuz closure, are driving conversation around Indonesia Energy Corp Ltd (INDO). The community anticipates a significant short squeeze and a major run, similar to other surging energy stocks, as traders rotate profits into INDO.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Amidst escalating geopolitical tensions, iShares Silver Trust ($SLV) is experiencing a sharp selloff, leading to intense community debate about its 'safe haven' status and widespread accusations of market manipulation. Many investors are seeing the dip as a significant buying opportunity, citing underlying physical supply shortages and robust industrial demand from the AI sector as bullish long-term drivers.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is actively trending as its dedicated community anticipates significant cultural and market momentum surrounding the upcoming 4/20, emphasizing the crypto's long-term vision for cannabis freedom and decentralization on Solana, and believing in its steady growth as a resilient "culture coin."

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending after reporting record-breaking full-year 2025 revenue and significant profitability improvements, backed by a multi-billion dollar AI infrastructure pipeline and strong cash reserves. Despite these positive fundamentals, the community is sharply divided, with many bulls expressing frustration over the stock's persistent undervaluation while skeptics question financial transparency and the lack of corresponding price appreciation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community conversation is dominated by the ongoing military operation in Iran, which many users are actively discussing as a strategic move to divert attention from recent developments regarding the Epstein files. This conflict fuels intense debate, with some viewing it as a strong, proactive measure, while others criticize the administration's rationale and potential for escalating global instability.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending due to surging safe-haven demand amidst escalating Middle East tensions and concerns over global stability, with the community actively debating if this marks a sustained gold rally or a temporary geopolitical spike.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is actively trending due to significant expansion in insurance coverage for its fibromyalgia drug, Tonmya, coupled with reports of accelerating sales and increased institutional buying, sparking intense community debate between bullish optimism for a potential short squeeze and long-standing concerns over dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio generated increased retail chatter on Monday after the company said that the FDA had awarded Orphan Drug Designation to its experimental CAR-T drug MB-101 for the treatment of astrocytomas and glioblastoma (GBM), two types of fast-growing brain tumors.The treatment, which targets the IL13Ra2 protein, is currently being studied in a Phase 1 trial.&nbsp;In early results published in Nature Medicine, MB-101 was well-tolerated, with 50% of patients seeing stable disease or better.&nbsp;Among them, two had partial responses, and two others achieved complete responses lasting 7.5 months and more than five and a half years.Mustang is also looking at a combo approach, pairing MB-101 with MB-108, an HSV-1-based oncolytic virus, in a regimen it calls MB-109.&nbsp;Preclinical studies suggest that MB-108 may help modify the tumor microenvironment, essentially turning "cold" tumors into "hot" ones to improve efficiency of MB-101 CAR-T cells.MB-108 already has Orphan Drug status for malignant glioma, and Mustang says the combination could allow MB-101 to move more effectively through the tumor, activate in the right spots, and target cancer cells more precisely.Both MB-101 and MB-108 are still enrolling patients in Phase 1 studies, including one at City of Hope, the other at The University of Alabama at Birmingham.&nbsp;However, moving the MB-109 program forward will depend on whether the company can secure more funding or land a partnership deal.Orphan Drug status gives MB-101 access to several FDA benefits, including seven years of market exclusivity if approved, tax breaks on clinical trial costs, and waived fees, which are all part of a program designed to support treatments for rare conditions affecting fewer than 200,000 people in the U.S.On Stocktwits, retail sentiment for Mustang Bio was ‘extremely bullish’ amid a 105,200% surge in 24-hour message volume.One user on Stocktwits suggested that shares of $MBIO could climb to the $15–$20 range if the company secures a partnership, noting the stock “has life” and is poised to grow, especially for those who bought in below $1.20.<stembedurl>https://stocktwits.com/Invest2live/message/620129007</stembedurl>Another user speculated that a partnership or buyout by a larger pharmaceutical company could be in play, calling the day’s FDA designation “great news” for&nbsp;<a href="https://stocktwits.com/symbol/MBIO">Mustang Bio</a>.<stembedurl>https://stocktwits.com/BostonBigBoyisBack/message/620124257</stembedurl>The stock has declined 68% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug

The company is advancing a novel combination of its CAR-T drug MB-101 and oncolytic virus MB-108, with both treatments currently enrolling patients in Phase 1 trials. 

Equity

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Mustang Bio Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

MBIO
Mustang Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MBIO News

MBIOMustang Bio Inc